公开(公告)号：US10709775B2

公开(公告)日：2020-07-14

申请号：US15751472

申请日：2016-07-26

Applicant: CELLECTIS

Inventor： Mathilde Dusseaux

IPC: A61K39/00 ,  C07K14/705 ,  C07K16/28 ,  A61K39/395 ,  C12N5/0783 ,  A61P35/00

Abstract: Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said CD38 immune by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.